Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rhonda Hettinger

Nurse Practitioner Clarksville, IN Nurse Practitioner

NPI 1407844996 CMS profile 10667872

1615 Blackiston View Dr, Suite E, Clarksville, IN 47129

Open in the dashboard

General payments

$37,578

784 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rhonda Hettinger of Clarksville, IN is reported in the CMS Open Payments database as having received $37,578 across 784 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,498 131
2024 General $6,553 162
2023 General $5,448 143
2022 General $8,870 149
2021 General $14,210 199

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rhonda Hettinger
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Rhonda Hettinger were reported at $2,498. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Rhonda Hettinger Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $14,210 $135 $40–$426 $132
2022 $8,870 $152 $48–$470 $149
2023 $5,448 $166 $54–$529 $160
2024 $6,553 $173 $55–$556 $164
2025 $2,498 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $23,841 132 payments
  2. Esperion Therapeutics, Inc. $4,387 23 payments
  3. AbbVie, Inc. $984 79 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $894 79 payments
  5. Novo Nordisk Inc $763 52 payments
  6. Regeneron Healthcare Solutions, Inc. $631 31 payments
  7. Novartis Pharmaceuticals Corporation $612 47 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $420 20 payments
  9. Amgen Inc. $402 24 payments
  10. Lilly USA, LLC $373 25 payments
  11. Other $4,272 272 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25,240 32 payments
  2. Food and Beverage $12,236 746 payments
  3. Education $88 5 payments
  4. Travel and Lodging $14 1 payment
Products named General payments · program years 2021–2025
  1. FARXIGA $23,092 95 payments
  2. NEXLETOL $4,387 23 payments
  3. NEXLIZET $4,146 9 payments
  4. TRINTELLIX $894 79 payments
  5. AIRSUPRA $585 21 payments
  6. VRAYLAR $477 41 payments
  7. LEQVIO $422 32 payments
  8. Kerendia $420 20 payments
  9. Ozempic $409 28 payments
  10. RYBELSUS $397 27 payments
  11. Other $8,720 548 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 141 drugs

Part D claims

11,080

Median for Nurse Practitioner: 389

Drug cost

$1,005,002

Median for Nurse Practitioner: $21,885

Branded share of claims

25.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 107 $142,721
Eliquis Apixaban Brand 154 $136,914
Xarelto Rivaroxaban Brand 57 $73,470
Trulicity Dulaglutide Brand 62 $67,242
Farxiga Dapagliflozin Propanediol Brand 66 $63,204
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 58 $51,359
Mounjaro Tirzepatide Brand 32 $34,467
Repatha Sureclick Evolocumab Brand 21 $32,595
Praluent Pen Alirocumab Brand 21 $31,267
Myrbetriq Mirabegron Brand 42 $27,748

The 10 drugs with the highest cost, of 141 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$65,851

Medicare's payments for the services billed

Medicare patients

227

Average age 72

Services billed

1,006

159 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 38%
Ischemic heart disease 33%
Diabetes 32%
Atrial fibrillation 15%
Chronic kidney disease 14%
COPD 12%
Depression 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
$4,137 66 —
AIRSUPRA
$244 — —
LEQVIO
$243 — —
UNITHROID
$149 — —
TRINTELLIX
$142 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

784 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record